Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ha! If you look at the posts on this board on morning of 10/8, some believed that this ticker was toast and heading into .002s. Within days it hit .07.. that's how fast this can move. With what can happen with this ticker it may be wise to have a solid position.
The company didn’t pump anything. They put out 8-K and then the pinkie players took it from there.. herd mentality took over and off it went!
Anything is possible! It may be Eiger is behind the whole ridgeway Inspyr deal! A way to get it’s prized employee a subsidiary to run and at the same time getting control of both of the adenosine and mipsagargin drug platforms! Stranger things have happened!
Looked at Eiger's 10-K.. a solid company more than capable to back COLIN in any dealings. Anything possible .. maybe Ridgeway will become subsidiary.
It was the 160's that held a week or so ago and then shot up.. maybe history can repeat the run!
I can't say you are wrong all I know is from the 8-K that Ridgeway has controlling interest in NSPX and COLIN HISLOP is CEO and President of Ridgeway. I have no reason to believe that COLIN is not controlling the company. However anything is possible. If some ones bias is negative or positive on this ticker there are reason on both sides to voice your position.
I highly doubt that COLIN HISLOP has hatched a wild and devious scheme to be launched on the unsuspecting investor as you surmise. I known he is an MD but DR. Evil doesn't fit his resume.
If they release good news the price will spike and leave behind all the self proclaimed expert "traders" who afraid of losing some of their pennies got out of the ticker and they will miss out on making dollars (typical pinkie move). Patience is a four letter word in the OTC
Some stood on the sideline after last RS while others averaged down to sub pennies and were able to make fine return on the spike to 7. The wrong place to be is NOT to have a healthy position in NSPX especially with Colin on board. Not to worry this ticker will go higher just as it has multiple times in the past. The Ridgeway Inspyr deal has just started lots more to come!
Good day + 17% hard not to take! Tried to take out .017 but didn't happen (no sellers at that price). A sharp move above .032 tomorrow will spring some momentum and bring back players who wanted to see how far this would break after the AS notice. Obviously it will have to hold Friday low but let's be optimistic with COLIN in control!
Tried a few times to take out Friday low but couldn’t find the sellers! Nice action so far in the pm!
Lowe and Cain were the financial and business experts.. how did that work out for everyone!
What you talking about.. I know all I need to know about Ridgeway.. COLIN HISLOP.. study his bio.. he's not going to tag his name and reputation to some scam loser.. he's no Chris Lowe or Michael Cain. LOL
You have to deal with the traders who go where the winds take them.. right now things have calmed while all see what is happening next. The wind of favor will return to this ticker.. this is NOT the old NSPX.
The more that comes out it more and more seems that the 8-K dated 10/8 was all to do about Ridgeway getting an avenue to finance their operations by taking over the public company INSPYR. Eventually (probably soon) Inspyr will be in name only with Colin Hislop controlling NSPX in all aspects. The private company Ridgeway will disappear as it morphs totally into NSPX. Nspx was going nowhere with the present non-management now there is a chance that Colin can not only develop the assets of Ridgeway but also the IP of Inspyr under the ticker NSPX.
Since it was down Fri on news of the AS increase but wasn't the wash out that it could have been and most of the sell off happened late fri afternoon (typical) and every one interested had time to understand that a massive amount of shares are NOT going to hit the market soon...and it may be smart to have a position in the ticker.. I would say that on the tail wind of the Ridgeway Deal it MAY rally. Only an opinion make your own.
If the recent news is able to have some stay power and the stock turns upward past 3 the peeps will be back pushing the stock higher. There may not be momentum to ride now but it can return quickly. The reality is additional shares won't be hitting the market for months.
If you can understand and study to anticipate the movements of HERD MENTALITY you can make some money on OTC stocks. Stock fundamentals, chart movement probabilities or possibilities, and long range projections mean very little. Buying and scalping short term moves is the main object of many. Most with patience that hold "pinkies" get burnt or get out with loses. When stocks lose momentum traders move on to others that may be breaking out leaving bag holders behind. DD is for others to do traders are too busy trying to catch the next move.
FYI.. The National Cancer Institute (NCI) had previously demonstrated that thaspigargin was ten-to-a-hundredfold more potent than traditional chemotherapeutic agents in killing all types of cells.[6] Thapsigargin kills cells irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers as well as cancer stem cells.
Thapsigargin is main ingredient in Mipsagargin!
Inspyr holds patent to the production of Mipsagargin!
Phyton will receive patent to commercially produce thapsigargin 11/3/20
Mipsagargin has Orphan Drug Status by FDA for liver cancer therapy until 2034
Inspyr (genspera) and Phyton have a strategic partnership for the manufacture of thapsigargin.
Did NSPX just raise the AS to finance a PH III clinical trial for liver cancer?????
Yes .. sell the 65 million on the open market. They didn't need Ridgeway to raise the AS .. They cold issue some preferred stock with the votes to get it thru like they did last 2 times. Both Ridgeway and Inspyr want NSPX to own the technology with an abundant amount of shares to sell to finance the development.
Colin Hislop (see bio) is a smart guy with gobs of experience. It's a bet that he already knows how NOVEL IMMUNO-ONCOLOGY DELIVERY TECHNOLOGY TARGETING ADENOSINE RECEPTOR ANTAGONISTS (RT-AR001) is going to be received in the bio world and how much it is worth. Along with the other existing IP of NSPX he is getting ready to take Inspyr to a much higher level.
Makes a lot of sense that Ridgeway gets 65mil shares of NSPX and immediately starts diluting them down to nothing per share with a boost of AS. Does anyone see something wrong with that picture? You would think That Colin Hislop as CEO of Ridgeway would want to increase PPS instead of run it into ground.
Something to think about over the weekend. Below is short bio of Colin Hislop, Ridgeway CEO. You can also do your own DD and investigation concerning who is involved with NSPX. Read it carefully then ask yourself if this person seems like a individual who is going to risk his reputation and years of expertise by getting involved in a stock scam to deplete the account of shareholders. Ridgeway and Inspyr are just getting started and positive events are on the way!
Colin Hislop, MD
SENIOR VICE PRESIDENT, CLINICAL AND DEVELOPMENT OPERATIONS
-
Colin Hislop has over 30 years of experience in drug development including small molecules, peptides and biologics, across therapeutic areas in both large pharma and start-up companies. Prior to joining Eiger full-time, Dr. Hislop was the Company’s senior medical advisor to the Progeria program and was instrumental to Eiger’s first NDA submission of Lonafarnib for the treatment of Progeria and Progeroid Laminopathies.
Prior to joining Eiger, Dr. Hislop served as Chief Medical Officer at Versartis and Anthera. He was previously Vice President and Head of Clinical Development at Peninsula Pharmaceuticals developing doripenem for systemic infections. Peninsula was acquired by J&J for $245 million. Dr. Hislop served as Vice President of Clinical Development at CV Therapeutics where he developed and filed an NDA for Ranexa for angina. CV Therapeutics was acquired by Gilead for $1.4 billion. He previously led the development of Actonel through initial FDA approvals for osteoporosis at Proctor & Gamble. Dr. Hislop began his industry career at Eli Lilly as Medical Director of Endocrinology for insulin and growth hormone. During his career, Dr. Hislop has been involved in all phases of drug development from IND to Phase 4, and has led numerous US, European, and global regulatory filings, including 4 NDAs.
Dr. Hislop earned a Bachelor of Science in Medical Biochemistry from the University of Surrey and a Bachelor of Medicine, Bachelor of Surgery (M.B.B.S.) at the University of London.
PH III Mipsagargin soon!
They will need investors money for the upcoming PH III Mipsagargin clinical trial now that PHYTON will have patent for PLANT CELL FERMENTATION process to produce abundant quantities of thapsigargin. Not a coincidence that PHYTON gets patent and NSPX increase AS in same week?
Seems like they are cleaning house and getting Sabby debentures paid off with new shares. It's Ridgeways company now and don't want to be under the thumb of a toxic lender. Plus there are developments that may run this stock hard and Ridgeway may feel they need stock to take advantage of future opportunities. Pick your poison increase AS or another RS..!
New sheriff in town making some changes..
Cash for pizza dinner tonight!
Don't be surprised to see that Ridgeway pays off Inspyr debenture debt that has accumulated over the yrs. In that way Ridgeway will have financial as well as operational control of the company. Sabby has done enough damage to NSPX and needs to get lost.
FYI.. Phyton Biotech received Patent No. 10822628 for the production of thapisgargin using PLANT CELL FERMENTATION technology on 10/14. The patent officially takes effect on 11/03/20 and extends for 20 yrs. This may help the value of mipsagargin! (thapisgargin is the active ingredient in mipsagargin and until now not available in large quantities)
You'll find out that some don't believe anything about this ticker. The Patents, Intellectual property, the results of clinical trials, the science behind the drug platforms, the intelligence of the scientist behind the drugs, the partnerships and agreements. Adenosine antagonists and mipsagargin is as foreign to them as moon rocks. It's all made up in some ones basement. The seventeen yrs and 60 million spent was an exercise in utter foolishness. Granted the stock performance has been dismal and financial agreements with toxic lenders to keep afloat have been a burden but it is bio and NSPX is still alive any anything can happen. A week ago no one knew that Ridgeway would have a controlling interest in the company. If your tied to a thirty minute candle chart this stock may not be for you.
This ticker has done exactly the same thing 3 times. 1.After RS#1.. pps slides to low sub pennies .. rallies to .04 because of Mipsagargin Ph II report then slides back to sub pennies. After RS #2.. pps slides back to sub pennies.. rallies to .04 because of Covid-19 hype then slides back to sub pennies. After RS#3.. pps slides back to low sub pennies now rallies to .03 on Ridgeway deal. Like they say three times is the charm.. this time may be the real deal. NSPX has resilience.. is the energizer bunny of the OTC. We'll see if history repeats itself or a change is in the wind.
The laundry is done for today. Investors got a good rinse and got cleaned! Lots of shares available to buy tomorrow!
Don't blame you for not reinvesting.. after stealing investors money with 3 RS in 3 yrs and a 4th probably in the works staying away from this ticker not a bad plan. But bio is bio and anything can happen. I felt that ridgeway was eventually going to buy the company. Hislop has many connections and no telling how much money is behind him. Now Ridgeway controls the company and gets paid to do it.. sweet deal for them. Lets see if they can do anything with Inspyr's IP.
You've been right on this ticker for months.. sorry you missed this little bounce.. good money has been had.
Buy low sell lower .. the flippers creed!
Ridgeway is now in control of Inspyr and #1 priority is to get NSPX out of OTC on to Nasdaq.. it may take some time but it will happen. Penny stock money won't cut the financial needs when the drug platforms owned by NSPX start addition development.
Notice from USPTO to PHYTON BIOTECH that patent for thapsigargin production was mailed to PHYTON today. Good news for NSPX for their drug mipsagargin.
Date Transaction Description
10-14-2020 Issue Notification Mailed
10-09-2020 Dispatch to FDC
Amazing how many after just three days of solid extraordinary gains want to jettison this ticker just because there was no follow thru to todays high. I guess they expect the PPS to go straight up! crazy!
It's called FOLP or FOMRM (fear of losing pennies or fear of making real money). They are real phobias..LOL